<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Anti-HER1 monoclonal antibody (mAb), panitumumab (Vectibix) is a fully human mAb approved by the FDA for the treatment of epidermal growth factor receptor (EGFR, HER1)-expressing <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>By combining the targeted specificity of panitumumab with the quantitative in vivo imaging capabilities of PET, we evaluated the potential of (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab PET/CT imaging and performed non-invasive, in vivo imaging of HER1 expression and estimated human dosimetry </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Panitumumab was radiolabeled with (89)Zr using a derivative of <z:chebi fb="0" ids="4356">desferrioxamine</z:chebi> (<z:chebi fb="0" ids="4356">DFO</z:chebi>-Bz-<z:chebi fb="7" ids="53203">NCS</z:chebi>) and with (111)In using CHX-A" <z:chebi fb="0" ids="35739">DTPA</z:chebi> as bifunctional <z:chebi fb="0" ids="38161">chelators</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Comparative biodistribution/dosimetry of both radiotracers was performed in non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> bearing athymic <z:mp ids='MP_0003815'>nude</z:mp> mice (n=2 females and n=2 males) over 1-week following i.v. injection of either using (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab or (111)In-CHX-A"-<z:chebi fb="0" ids="35739">DTPA</z:chebi>-panitumumab </plain></SENT>
<SENT sid="4" pm="."><plain>Micro-PET/CT imaging of female athymic <z:mp ids='MP_0003815'>nude</z:mp> mice bearing human <z:hpo ids='HP_0003002'>breast cancer</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (n=5 per <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> group) with variable HER1-expression very low (BT-474), moderate (<z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-231), and very high (<z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-468) was performed at over 1 week following i.v. injection of (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Radiochemical yield and purity of (89)Zr-Panitumumab was &gt;70% and &gt;98% respectively with specific activity 150 Â± 10 MBq/mg of panitumumab in a ~4 hr synthesis time </plain></SENT>
<SENT sid="6" pm="."><plain>Biodistribution of (111)In-CHX-A" <z:chebi fb="0" ids="35739">DTPA</z:chebi> -panitumumab and (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab in athymic non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> bearing <z:mp ids='MP_0003815'>nude</z:mp> mice displayed similar percent injected dose per gram of tissue with prominent accumulation of both tracers in the lymph nodes, a known clearance mechanism of panitumumab </plain></SENT>
<SENT sid="7" pm="."><plain>Also exhibited was prolonged blood pool with no evidence of targeted accumulation in any organ </plain></SENT>
<SENT sid="8" pm="."><plain>Human radiation dose estimates showed similar biodistributions with estimated human effective doses of 0.578 and 0.183 mSv/MBq for (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab and (111)In-CHX-A"-<z:chebi fb="0" ids="35739">DTPA</z:chebi>-panitumumab, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Given the potential quantitative and image quality advantages of PET, imaging of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> bearing mice was only performed using (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab </plain></SENT>
<SENT sid="10" pm="."><plain>Immuno-PET imaging of (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab in mice bearing <z:hpo ids='HP_0003002'>breast cancer</z:hpo> xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with variable HER1 expression showed high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake (SUV &gt;7) in the <z:chebi fb="14" ids="32506">MDA</z:chebi>-MB-468 high HER1-expressing mice and a strong correlation between HER1-expression level and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake (R(2)= 0.857, P &lt; .001) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab can prepared with high radiochemical purity and specific activity </plain></SENT>
<SENT sid="12" pm="."><plain>(89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab microPET/CT showed uptake corresponding to HER-1 expression </plain></SENT>
<SENT sid="13" pm="."><plain>Due to poor clearance, initial dosimetry estimates suggest that only a low dose (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab shows favorable human dosimetry; however due to high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake, the use of (89)Zr-<z:chebi fb="0" ids="4356">DFO</z:chebi>-panitumumab is expected to be clinically feasible </plain></SENT>
</text></document>